camptothecin has been researched along with etirinotecan pegol in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brünner, N; Nielsen, DL | 1 |
| Awada, A; Barrett-Lee, PJ; Chan, S; Chia, YL; Cocquyt, V; Coleman, RE; Garcia, AA; Hamm, JT; Hannah, AL; Hoch, U; Huizing, MT; Jerusalem, GH; Mehdi, A; O'Reilly, SM; Perez, EA; Sideras, K; Young, DE; Zhao, C | 1 |
| Eldon, MA; Hoch, U; Johnson, RK; Staschen, CM | 1 |
| Chia, YL; Eldon, MA; Gordi, T; Hoch, U; Sy, SKB | 1 |
1 trial(s) available for camptothecin and etirinotecan pegol
| Article | Year |
|---|---|
Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Camptothecin; Drug Administration Schedule; Europe; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Intention to Treat Analysis; Irinotecan; Kaplan-Meier Estimate; Middle Aged; Polyethylene Glycols; Time Factors; Topoisomerase I Inhibitors; Treatment Outcome; United States | 2013 |
3 other study(ies) available for camptothecin and etirinotecan pegol
| Article | Year |
|---|---|
Etirinotecan pegol: an option for late-stage breast cancer?
Topics: Breast Neoplasms; Camptothecin; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Irinotecan; Polyethylene Glycols; Topoisomerase I Inhibitors | 2013 |
Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models.
Topics: Animals; Antineoplastic Agents; Camptothecin; Dogs; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Irinotecan; Male; Mice; Mice, Nude; Mice, SCID; Neoplasms, Experimental; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Species Specificity; Topoisomerase I Inhibitors; Treatment Outcome; Xenograft Model Antitumor Assays | 2014 |
Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Female; Glucuronosyltransferase; Heterocyclic Compounds, 4 or More Rings; Humans; Irinotecan; Male; Middle Aged; Models, Biological; Neoplasms; Polyethylene Glycols | 2018 |